Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 first-in-human study of CodaVax-DENV

Next Previous
Trial Profile

A Phase 1 first-in-human study of CodaVax-DENV

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 27 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CDX DENV (Primary)
  • Indications Dengue
  • Focus Adverse reactions; First in man; Pharmacodynamics

Most Recent Events

  • 27 Oct 2023 New trial record
  • 24 Oct 2023 According to a Codagenix media release, the US Department of Defense (DoD), through the US Army Medical Research and Development Command and the US Army Medical Research Acquisition Activity, has awarded the Company dollar 5.88 million to advance the development of CodaVax-DENV vaccine program. The funds will support good manufacturing practices (GMP) of drug substances and tetravalent drug product for a Phase 1 study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top